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Previously  we  have  shown  that intradermal  (i.d.)  immunization  with  a recombinant  adenovirus  express-
ing antigen  85A  (Ad85A)  induced  a strong  splenic  CD8  T cell  response  in BALB/c  mice  but  a weak  lung
immune  response  and  did not  protect  mice  against  challenge  with  Mycobacterium  tuberculosis  (Mtb).  After
moving  to a  new  animal  house,  the  same  i.d.  immunization  induced  a  strong  lung  immune  response  and
the mice  were  protected  against  Mtb  challenge.  Increased  numbers  of  antigen  85A-speciﬁc  CD8  cells  were
present  in  lung  tissue  but  were  not  recoverable  by  bronchoalveolar  lavage  (BAL).  Mycobacterial  growth
was  inhibited  21  days  after  Mtb  challenge.  In  contrast,  the  effects  of  intranasal  (i.n.)  immunization  did
not change  between  the  animal  houses;  85A-speciﬁc  T  cells  were  recovered  by  BAL  and  were  able  to
inhibit Mtb  growth  early  after  challenge.  The  effect  of alterations  to the  environment  was  investigated  by
administering  BCG  or Mycobacterium  abscessus  in  the  drinking  water,  which  induced  protection  against
Mtb  challenge,  while  Mycobacterium  smegmatis  did  not. However,  when  Ad85A  was  given i.d.  at  the same
time  as  BCG  or  M.  abscessus,  but  not  M. smegmatis,  the protection  induced  by Ad85A  was  abolished.  Treat-
ment  of  mice  with  a CD25  antibody  during  the  challenge  period,  abolished  the  suppressive  effect  of  oral
mycobacterial  administration,  suggesting  that  regulatory  T cells  (T regs)  were  involved.  These results
showed  that  exposure  to  environmental  microorganisms  can  alter  the  protective  immune  response  to
a  parenterally  administered  subunit  vaccine,  a  result  with  important  implications  for  the  use  of  such
vaccines  in  humans.. Introduction
Tuberculosis (TB) remains an important healthcare problem
ausing 1.5 million deaths a year. An effective vaccine would alle-
iate the problem but in spite of much effort, BCG remains the only
icensed vaccine. BCG protective efﬁcacy varies widely in differ-
nt geographical areas [1],  perhaps because of varying exposure
o environmental mycobacteria (EM). Immunity to EM may  inhibit
CG multiplication and prevent the induction of an efﬁcient pro-
ective immune response [2].  Alternatively EM-induced immunity
ay  mask BCG induced protection [3] or induce regulatory T cells
T regs) [4].
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We  have used Ad85A, to explore the contributions of local and
systemic immunity to protection against Mtb. In BALB/c mice this
vaccine induces a powerful CD8 T cell response and weak CD4
response and there is strong published evidence that the CD8  T cells
mediate protection [5,6].
Using this model we  have shown that both local pulmonary and
systemic immunity are important in protective immunity against
Mtb. Local immunity inhibits the growth of Mtb  very early after
challenge infection, while systemic immunity acts later. Further-
more, local and systemic immunity can have additive protective
effects [7,8]. Induction of local immunity might therefore be a useful
strategy for future Mtb vaccines. However, lung as well as sys-
temic immunity is affected by environmental microbial exposure.
Thus for example, infection with Helicobacter can suppress aller-
gic lung responses [9] and responses to inﬂuenza virus can also
be modulated [10], although the effects of microbial exposure on
lung immune responses to parenterally administered Mtb  subunit
Open access under CC BY license.vaccines have not been investigated.
Our earlier experiments on immune response and protection
induced by i.d. and i.n. administration of Ad85A were carried out
using mice supplied as speciﬁc pathogen free (SPF) animals but
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aintained in the animal house in open top cages (OTC) [7,11].
hen we moved to a new facility, in which identical mice were
oused in individually ventilated cages (IVCs), we found that both
mmune responses and protection induced by the same vaccine
ere profoundly altered. Whereas previously Ad85A i.d. generated
 strong splenic, but only a very weak lung immune response and
he mice were not protected against challenge [11], after moving,
e observed that Ad85A i.d. induced a strong antigen-speciﬁc CD8 T
ell response in the lungs. The immune response and protection
nduced by Ad85A i.n. were unaffected by the change of animal
ouse. As most of the subunit Mtb  vaccines that are in advanced
linical trials are administered parenterally [12] we  investigated
hether the altered immune response to Ad85A i.d. correlated with
rotection and why lung immune responses of the same strain of
ice, immunized with the same vaccine, differed in the two  animal
ouses.
. Materials and methods
.1. Mice and immunization
All experiments were performed with 6–8 week old female SPF
ALB/c mice (Harlan Orlac, Blackthorn, UK), were approved by the
nimal use ethical committee of Oxford University and complied
ith UK Home Ofﬁce guidelines. In one animal facility, mice were
oused in OTCs and drank tap water. In the second facility, the mice
ere kept in IVCs and given water puriﬁed by reverse osmosis.
For i.d. immunization, BALB/c mice were anesthetized with
soﬂuorane and injected with 25 l PBS in each ear, containing
 × 109 virus particles of Ad85A per mouse, and for i.n. immuniza-
ion allowed slowly to inhale 40 l of PBS containing 2 × 109 virus
articles of Ad85A [7].
T  regs were depleted by 3 intraperitoneal (i.p) injections of 80 g
nti-CD25 antibody (clone PC61) one day before and 7 and 14 days
fter Mtb  challenge. Control mice received 80 g normal rat Ig
Abcam, Cambridge, UK).
.2. Oral exposure to mycobacteria
BCG (Statens Serum Institute, Copenhagen, Denmark), Mycobac-
erium abscessus (kindly provided by Dr Sandra Newton, Imperial
ollege, London) or Mycobacterium smegmatis (kindly provided by
r Kathryn Lougheed, Imperial College, London) were administered
n the drinking water. M.  abscessus and M.  smegmatis were cultured
n 25 ml  LB broth supplemented with 10% OADC (oleic acid, albu-
in, dextrose and catalase, Sigma) at 37 ◦C with shaking. After 48 h
he cultures were centrifuged at 600 × g for 10 min and the pellets
esuspended in 500 ml  of reverse osmosis water in the cage bot-
les. Ten vials of BCG (SSI) were similarly suspended in 500 ml  of
ater. Mycobacterial colony forming units (CFU) were enumerated
y plating on 7H11 Middlebrook agar plates (E&O Laboratories Ltd.,
onnybridge, UK) and counting colonies after incubation. Mycobac-
erial concentration was between 103 and 104 CFU/ml of water.
fter 1 week, M.  abscessus and M.  smegmatis remained at the same
oncentration, however no viable BCG was recovered. Water bot-
les containing mycobacteria were changed weekly.
.3. Isolation of lymphocytes from lungs, BAL and spleen
Lungs were perfused with PBS, cut into pieces and digested with
.7 mg/ml  collagenase type I (Sigma) and 30 g/ml DNase I (Sigma)
or 45 min  at 37 ◦C. Digested fragments were crushed through a
ell strainer using a syringe plunger, washed, layered over Lym-
holyte (Cederlane, Ontario, Canada) and centrifuged at 1000 × g
or 25 min. Interface cells were collected and washed. BAL was1 (2013) 1086– 1093 1087
collected by washing via the trachea. The collected cells were cen-
trifuged and resuspended in medium. Spleens were passed through
a cell strainer using a syringe plunger, red blood cells were removed
with lysis buffer (Qiagen, Crawley, UK) and the cells were washed.
2.4. Flow cytometry
Cells were cultured in Hepes buffered RPMI, 10% heat-
inactivated FCS, l-glutamine, penicillin and streptomycin for 6 h.
Cells from Ad85A immunized animals were stimulated for 6 h
with either 66 15-mer peptides overlapping by 10 amino acids
covering the 85A protein sequence or with 3 peptides (Peptide
Protein Research Ltd., Fareham, UK) encoding the dominant CD4
(Ag85A99–118aa TFLTSELPGWLQANRHVKPT) and CD8 (Ag85A70–78aa
MPVGGQSSF and Ag85A145–152aa YAGAMSGL) peptide epitopes [7]
(Peptide Protein Research Ltd.). Each peptide was 2 at g/ml. After
2 h at 37 ◦C, Golgi Plug (BD Biosciences, Oxford, UK) was  added
according to the manufacturer’s instructions.
Cells were washed and incubated with CD16/CD32 monoclonal
antibody to block Fc binding. Subsequently the cells were stained
for CD4 (RM4-5), CD8 (53-6.7) (BD Bioscience, Oxford, UK), anti
I-A/I-E (2G9), CD25 (PC61.5), CD11c (HL3), then for intracellular
FoxP3 (FJK-16s), IFN (XMG1.2), IL-2 (JES6-5H4) and TNF (MP6-
XT22) (eBioscience, Hatﬁeld, UK) using the BD Cytoﬁx/Cytoperm kit
according to the manufacturer’s instructions. Cells were ﬁxed with
PBS + 1% paraformaldehyde, run on a LSRII (BD Biosciences) and
analyzed using FlowJo software (Tree Star Inc., Ashland, Oregon,
USA).
2.5. Infection with Mtb  and determination of mycobacterial load
Five to 7 mice were anesthetized with isoﬂurane and infected
i.n. with Mtb  (Erdman strain, kindly provided by Dr Amy  Yang,
CBER/FDA) in 40 l PBS. Lung CFU were enumerated 24 h after
challenge to determine the number of organisms deposited (∼200
CFU). Mice were sacriﬁced at indicated times, the lungs and spleen
homogenized and mycobacterial load determined by plating 10-
fold serial dilutions of tissue homogenates on Middlebrook 7H11
agar plates (E&O Laboratories Ltd., Bonnybridge, UK). Colonies were
counted after 3–4 weeks of incubation at 37 ◦C in 5% CO2.
2.6. Statistical analysis
Data were analyzed using one-way ANOVA followed by Tukey’s
multiple comparison test. Immune responses were assessed using
Mann Whitney test.
3. Results
3.1. Effect of the environment on Ad85A i.d. induced immune
responses and protection
The responses of mice immunized with Ad85A i.d. or i.n. in
OTCs or IVCs were compared, although the experiments could not
be performed simultaneously because the OTC facility had been
demolished by the time experiments were performed in the IVC
facility. IVC mice immunized with Ad85A i.d. made a very strong
lung 85A-speciﬁc CD8 T cell response, with ∼12% of CD8 cells pro-
ducing IFN, compared to 0.7% for OTC Ad85A i.d. immunized mice
(Fig. 1A) [6,11,13]. There was no increase in the number of lung lym-
phocytes and percentage of CD8 T cells in IVC Ad85A i.d. compared
to unimmunized mice.The lung response to Ad85A i.n. and splenic responses to the
vaccine given by either route were unchanged (Fig. 1A), as were
CD4 responses, which were always low for this vaccine and strain
of mice [5,7,11]. Although Ad85A i.d. induced a much stronger lung
1088 P. Beverley et al. / Vaccine 31 (2013) 1086– 1093
Fig. 1. T cells responses and protection against Mtb in different animal facilities. (A) Cytokine responses of T cells to antigen 85A. BALB/c mice were immunized with Ad85A
i.d.  or i.n. in an animal house with open top cages (OTC) or an animal house with individually ventilated cages (IVC). Lung and splenic lymphocytes were isolated 5 weeks
post  immunization and stimulated with pooled 85A peptides. The percentage of CD8+ cells expressing IFN was  determined by ﬂow cytometry. Error bars show SD. (B) Mtb
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hey  were challenged with Mtb and lung CFU enumerated 5 weeks later. Data from
rom  naïve or between the indicated groups, one-way ANOVA with Tukey’s post tes
D8 response in IVCs than Ad85A i.n. (12.1% i.d. versus 2.8% i.n.), the
roportions of single, double or triple IL-2, TNF and IFN cytokine
roducing cells, did not differ greatly between mice immunized by
he two routes, as shown previously [7,11].
When mice were immunized in OTC, the magnitude of lung
ut not splenic immune responses, correlated with protection after
d85A immunization [11]. We  therefore tested whether this was
he case in IVCs. Ad85A i.d. or i.n. mice were challenged 5 weeks
r 8 months after immunization and Mtb  lung CFU assessed 5
eeks later. The lung mycobacterial load was reduced by 0.8 log10
n Ad85A i.d. immunized compared to naïve animals, while Ad85A
.n. mice showed a 1.5 log10 reduction (Fig. 1B). Protection of the
ungs after Ad85A i.d. or Ad85A i.n. was sustained for up to 8 months
Fig. 1C). The effect of Ad85A i.d. on spleen CFU was inconsistent,
ith no reduction in the experiments shown in Fig. 1B and C, but
 reduction in others (Fig. 3A). In contrast Ad85A i.n. consistentlyere immunized with Ad85A i.d. or Ad85A i.n. One month (B) or 8 months (C) later
two  experiments with 5–7 mice/group are shown. ***p < 0.001, **p < 0.01, *p < 0.05
reduced splenic CFU, suggesting that i.n. immunization may  reduce
dissemination as well as lung Mtb growth.
These data showed that environmental changes profoundly
altered the lung antigen-speciﬁc response and protection after
Ad85A i.d. immunization, and conﬁrmed that lung immune
responses, although not their magnitude, correlated with protec-
tion after Ad85A immunization. For the ﬁrst time we showed that
Ad85A i.d. could induce sustained protection, although protection
afforded by Ad85A i.n. was  always superior, despite the higher lung
immune response to Ad85A i.d.
3.2. The location of antigen-speciﬁc cells and kinetics of Mtb
growth after Ad85A i.d. and Ad85A i.n. immunization
Previously, intranasal immunization with Ad85A or recombi-
nant 85A protein, was  shown to inhibit Mtb  growth in the ﬁrst
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eek after challenge and antigen speciﬁc-cells were found in BAL,
hile effective parenteral vaccines inhibited Mtb  growth later and
o antigen speciﬁc cells were found in BAL [6–8]. We  therefore
nalyzed BAL in Ad85A i.d. and i.n. animals maintained in IVCs and
etermined the kinetics of Mtb  growth after challenge.
BAL was collected from Ad85A i.n. and Ad85A i.d. mice 4 weeks
ost-immunization. CD8+ T cells were abundant in BAL of Ad85A
.n. but scanty in BAL of Ad85A i.d. mice. In Ad85A i.n. mice, ∼10%
f BAL CD8 cells were 85A-speciﬁc producing IFN in response
o stimulation with 85A peptides, and many expressed CXCR6+
Fig. 2A) [6–8]. Very few antigen speciﬁc T cells were found in
AL of Ad85A i.d. mice, even though a greater proportion of 85A
peciﬁc CD8 T cells were found in lung tissue (Fig. 1A). Thus the
ocalization of 85A-speciﬁc cells differed between Ad85A i.n. and
.d. immunized mice.
To examine the kinetics of mycobacterial growth, Ad85A i.n. or
d85A i.d. mice were sacriﬁced 7, 14, 21 and 28 days post Mtb chal-
enge. As before [7],  Ad85A i.n. mice inhibited Mtb growth at day 7,
hile i.d. animals did not do so until day 21 (Fig. 2B). Thus although
oth Ad85A i.d. and i.n. animals had antigen speciﬁc cells in the
ungs (Fig. 1A), only Ad85A i.n. mice had 85A-speciﬁc cells in BAL
nd inhibited early Mtb  growth (Fig. 2A and B).
.3. Effect of mycobacterial exposure on Ad85A i.d. induced
rotection
Microbial exposure of mice in OTCs drinking tap water, is likely
o differ from mice in IVCs drinking puriﬁed water. We  analyzed
mmune responses to Ad85A i.d. in several OTC and IVC facili-
ies, but in all observed large lung responses, suggesting that the
riginal facility had some unique environmental property. How-
ver, this is not the ﬁrst time that unique responses of mice from
ne animal house have been described, as C57BL/6 J mice differ in
ntestinal ﬂora and in the number of Th17 cells in the intestine,
rom C57BL/6 mice from all other suppliers [14]. Therefore, rea-
oning that microbial exposure, most likely in drinking water might
xplain the effects of our former facility, we tested the effect of dif-
erent mycobacteria administered orally on protection induced by
d85A i.d.
Mice were immunized with Ad85A i.d. and given BCG in the
rinking water from the day of immunization until challenged with
tb  after 5 weeks. Unimmunized mice were also given BCG water.
nimmunized animals given BCG water showed 0.6 log10 CFU less
han controls with clean water (Fig. 3A), in accordance with evi-
ence that oral BCG induces protective immunity [15]. Ad85A i.d.
lone also reduced Mtb  growth by 0.9 log10. Strikingly Ad85A i.d.
nd BCG water were not additive, but instead Mtb growth was
he same as in mice given BCG water alone (0.6 log10). BCG water
lone did not affect spleen CFU, although together with Ad85A i.d.
t reversed the splenic protective effect of Ad85A i.d.
We next tested M.  abscessus, which is found in water and this
lone reduced lung CFU by 1.3 log10 (Fig. 3B) but like BCG, abolished
he protection afforded by Ad85A i.d. Heat killed M.  abscessus or live
.  smegmatis in the water did not protect against Mtb  nor did they
ffect protection induced by Ad85A i.d. (Fig. 3B and C).
To investigate the mechanisms of these effects on Ad85A i.d.
nduced protection, we measured 85A-speciﬁc responses in the
ungs and spleen 4–5 weeks after immunization. In 2 out of 4 exper-
ments there were reduced numbers of 85A-speciﬁc CD8 T cells in
he lungs of Ad85A i.d. mice given BCG or M.  abscessus water but no
hange in spleen responses (not shown). The supernatants of 48 h
ung and spleen cell cultures stimulated with 85A peptides were
lso assayed for cytokines, but there were no consistent differences
etween mice given only Ad85A i.d. and those given Ad85A with
ycobacteria in the water (not shown).1 (2013) 1086– 1093 1089
3.4. Depletion of T regs abolishes the inhibitory effect of M.
abscessus on Ad85A i.d. protection
Exposure to antigens in the gut induces regulatory T cells (T
regs) and T regs have been shown to inhibit protective immune
responses to Mtb  [16–18].  We  therefore used CD25 antibody, given
the day before and 7 and 14 days after Mtb challenge, to deplete T
regs from immunized and mycobacteria-exposed mice. Two days
after the ﬁrst administration of CD25 antibody, CD4+CD25+Foxp3+
cells decreased by ∼55% in the lungs and spleen and 4 days after the
second administration by ∼68%, indicating a sustained depletion
of CD4+CD25+Foxp3+ T regs, a result similar to those obtained by
others [19]. Control rat Ig had no effect.
CD25 depletion alone reduced Mtb CFU by 0.6 log10, in the lung
and M. abscessus alone was  also protective (Fig. 4A), while inhibiting
the protective effect of Ad85A i.d. (Fig. 4B). CD25 depletion had no
effect on Ad85A i.d. induced protection but reversed the inhibitory
effect of M. abscessus on Mtb load in the lungs and spleen. Control
rat Ig had no effect (Fig. 4B).
These data indicated that depletion of CD4+CD25+Foxp3+ cells
reversed the inhibitory effect of M. abscessus on Ad85A i.d. induced
protection, suggesting that T regs may  be involved.
4. Discussion
In BALB/c mice Ad85A induces a predominantly CD8 T cell
response. Cell transfer experiments and in vivo depletion of CD4 T
cells suggest strongly that the CD8 T cells are protective against Mtb
[5,6]. We  have used this model to explore the contributions of local
and systemic immunity to protection against pulmonary challenge
and have shown that local immunity is highly protective, most
likely because lung resident T cells can act immediately against
Mtb at the portal of entry [7].  It is also clear that the localization
of immune cells in the lungs after i.n. and i.d. immunization differs
and that this may  also contribute to the efﬁcacy of i.n. immunization
(Figs. 1 and 2) [5,6].
However, because most current clinical trials of subunit Mtb
vaccines have used parenteral routes of immunization [12] and
we observed striking differences in the lung immune response to
Ad85A i.d. but not Ad85A i.n. in different environments, here we
have focused on the effect of environmental factors on protection
induced by parenteral Ad85A immunization. In OTCs in the animal
facility we  ﬁrst used, A85A i.d. induced very few lung antigen-
speciﬁc cells. In contrast in all other OTC and IVC facilities, Ad85A
i.d. generated large 85A-speciﬁc lung CD8 T cell populations (Fig. 1).
Signiﬁcant protection against Mtb was  induced in IVCs but was
always less than protection conferred by Ad85A i.n. Inhibition of
Mtb growth occurred late after challenge, as with other parenteral
vaccines [8].  Protection was  long lasting, in contrast to the reported
effect of intra-muscular Ad85A, which conferred protection at 4
but not 12 weeks [20]. Thus the change from OTCs in the original
animal house to new conditions correlated with the presence of
an increased number of antigen speciﬁc T cells in the lungs and
improved protection against Mtb after Ad85A i.d. immunization.
While immunization with Ad85A i.d. was greatly affected by
the environment, immunization with Ad85A i.n was not. Ad85A
i.n induces a lung resident self-maintaining protective population
and [6,11,21] which includes a BAL population whose presence
correlates with inhibition of Mtb growth early after challenge [6].
Many BAL cells express CXCR6+ and also bind MHC-85A peptide
tetramers [6] but we  have not yet determined whether iNKT cells
expressing CXCR6 also contribute to early inhibition of Mtb growth
[22]. These data indicate that the environmental effects of OTCs
or IVCs, have a more profound inﬂuence on lung homing cells
1090 P. Beverley et al. / Vaccine 31 (2013) 1086– 1093
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Fig. 2. Location of cells and kinetics of Mtb  growth after Ad85A immunization. (A) BALB/c mice in IVCs were immunized with Ad85A i.d. or i.n. Four weeks post immunization
BAL  was collected from individual mice and the number of CD8+, CD8IFN+ and CD8CXCR6+ cells determined by ﬂow cytometry. The ﬁgures show the mean number of each
cell  population recovered ±SD from 3 mice in one of three independent experiments ***p ≤ 0.005. (B) Kinetics of Mtb  growth after Ad85A i.d. and i.n. immunization. BALB/C
mice  were immunized in IVCs once with Ad85A i.d. or i.n. Five weeks after immunization mice were challenged with Mtb  and groups of 5 mice sacriﬁced 7, 14, 21 and 28
days  later for enumeration of lung Mtb  CFU. ***p < 0.001, *p < 0.05 compared to naïve animals, one-way ANOVA with Tukey’s post test. Representative data from one of two
experiments are shown.
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*p  < 0.01, *p < 0.05 compared to naïve animals with clean water, one-way ANOVA w
nduced by parenteral immunization than the lung resident popu-
ation induced by i.n. immunization.
We  reasoned that the difference in immune responses (Fig. 1A),
ight be due to varying microbial exposure in different ani-
al  houses and might be mimicked by adding mycobacteria to
he drinking water concurrently with immunization. This does
ot prevent entry of 85A-speciﬁc T cells into the lungs after i.d.
mmunization, although the percentage is lower in 2 out of 4 exper-
ments. However, the protective effect of Ad85A i.d. is reduced
hen BCG or M.  abscessus are administered orally (Fig. 3). Num-
ers of CD4+CD25+FoxP3+ T regulatory cells in the lungs, spleen
r mesenteric nodes are unaltered after concurrent immunizationgmatis (M sm)  (C). Five weeks after Ad85A i.d. immunization they were challenged
FU. Data from one of two  experiments with 5–7 mice/group are shown. ***p < 0.001,
ukey’s post test.
with Ad85A and oral mycobacteria, although in vivo CD25 treat-
ment abolishes the inhibitory effect of oral mycobacteria on Ad85A
i.d. induced protection. Similarly unchanged numbers of T regs are
observed in other models where they have functional effects [16],
so that it remains possible that oral BCG or M.  abscessus induce T
regs that affect lung immune cells. It is also known that T regs can
decrease protection against Mtb [16].
It is clear that events in the intestine can inﬂuence lung immu-
nity. For example, Helicobacter pylori infection can prevent the
induction of lung allergic disease [9] and the gut microbiota
inﬂuences the response to lung inﬂuenza virus infection [10]. Alter-
ations in both lung dendritic cells and T reg function have been
1092 P. Beverley et al. / Vaccine 31 (2013) 1086– 1093
Lungs - un immun ise d
N
N
 +
 M
 a
bs
N
 +
 C
D
25
N
 +
 r
at
 Ig
4
5
6
7
8
* *
L
o
g
 C
F
U
 p
e
r 
lu
n
g
Splee n -  unimmun ise d
N
N
 +
 M
 a
bs
N
 +
 C
D
25
N
 +
 r
at
 Ig
3
4
5
6
* *
L
o
g
 C
F
U
 s
p
le
e
n
 Lung s - Ad85 A i.d.
N
A
d8
5A
 i.
d.
A
d8
5A
 i.
d.
 +
 M
 a
bs
A
d8
5A
 i.
d.
 +
 C
D
25
A
d 
+ 
M
 a
bs
/C
D
25
A
d8
5A
 i.
d.
 +
 M
 a
bs
/ra
tIg
4
5
6
7
8
* **
L
o
g
 C
F
U
 p
e
r 
lu
n
g
Splee n  -  Ad85 A i.d.
N
A
d8
5A
 i.
d.
A
d8
5A
 i.
d.
 +
 M
 a
bs
A
d8
5A
 i.
d.
+ 
C
D
25
A
d 
+ 
M
 a
bs
/C
D
25
A
d8
5A
 i.
d.
 +
 M
 a
bs
/r
at
 Ig
3
4
5
6
***
L
o
g
 C
F
U
 s
p
le
e
n
A
B
l ng - uni munized spleen - unimmunized
lung  - Ad 85A i.d. spleen - Ad 85A i.d.
Fig. 4. Mtb CFU after CD25 depletion. Unimmunized (N) or Ad85A i.d. immunized BALB/c mice in IVCs were given drinking water with or without M.  abscessus (M abs).
F ther 5
7  i.p. R
* er, one
d
C
C
a
s
a
n
i
a
T
m
t
s
s
a
g
m
i
b
E
b
a
c
e
aive  weeks after the immunization they were challenged with Mtb i.n. and after fur
 and 14 after the Mtb  challenge, mice were given CD25 antibody or control rat Ig
**p  < 0.001, **p < 0.01, *p < 0.05 compared to unimmunized animals with clean wat
escribed in these models. In germ free mice increased numbers of
XCR6+ iNKT cells are found in colon and lung due to increased
XCL16 expression and both colitis and lung allergic responses
re increased [22]. In other tissues however, fewer iNKT cells are
een in germ free animals. Such effects may  also be unique to one
nimal house. Thus it was found that C57BL/6J mice lacked intesti-
al Cytophaga-Flavobacteria-Bacteroides (CFB) commensals that
nduce lamina propria (LP) Th17 cells during development, while
ll other C57BL/6 mice tested have CFB and a greater number of LP
H17 cells [14]. While we  have not demonstrated changes in the
icrobiota, we have shown that short term exposure to mycobac-
eria has an effect on lung immunity and that this is organism
peciﬁc, as illustrated by the different effects of BCG and M.  absces-
us compared to M.  smegmatis.  In addition to microbial effects on
daptive immune responses, parenteral BCG administration alters
ene expression in lung stromal components [23], so that several
echanism may  contribute to the down-regulation of protective
mmune responses to Ad85A i.d. observed here.
The variation in BCG effectiveness in different locations [1] has
een ascribed to environmental effects, including exposure to EM.
xperimentally, parenteral pre-immunization of mice with EM can
lock induction of protective immunity to Mtb  by BCG, but did not
ffect immunity induced by a subunit vaccine [2].  In contrast con-
urrent oral exposure to mycobacteria, a route more akin to likely
xposure in the ﬁeld, profoundly affected immunity to a parenteral
deno-based subunit vaccine. weeks sacriﬁced for enumeration of lung and spleen Mtb  CFU. The day before and
epresentative data from one of two experiments with 5–7 mice/group are shown.
-way ANOVA with Tukey’s post test.
We  show that an altered environment changes the distribution
of immune cells in mice immunized parenterally with this adeno-
based subunit vaccine and that the altered distribution correlates
with protection after Mtb challenge. Furthermore, exposure to oral
EM can abolish protective immunity induced by the same subunit
vaccine. These results have important implications for the devel-
opment and application of parenteral subunit vaccines as boosters
for use after BCG priming. Better understanding of the mechanisms
underlying environmental effects may  lead to the development of
new strategies to improve the efﬁcacy of such vaccines.
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